Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | FNTA | P49354 | 4/20 | 0.48 |
| ▸ | FNTB | P49356 | 4/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10806849 | 0.82 | ATM (0.54) | CYP11B1CYP11B2ATMRXFP1 | |
| SCHEMBL11037967 | 0.76 | FNTA (0.47) | FNTAFNTBPKMMAPK10VKORC1 | |
| SCHEMBL12425596 | 0.75 | TBXAS1 (0.56) | TBXAS1FNTAFNTB | |
| SCHEMBL11561617 | 0.74 | TAAR1 (0.57) | TBXAS1 | |
| SCHEMBL13408067 | 0.73 | TBXAS1 (0.56) | TBXAS1 | |
| SCHEMBL6216616 | 0.72 | CHRNB2 (0.55) | TBXAS1PKM | |
| SCHEMBL11048258 | 0.71 | FNTA (0.51) | FNTAFNTBPKMMAPK10VKORC1 | |
| SCHEMBL11346119 | 0.70 | TBXAS1 (1.00) | TBXAS1CYP11B1CYP11B2 | |
| SCHEMBL8253461 | 0.70 | CHRNB2 (0.56) | TBXAS1 | |
| SCHEMBL11048261 | 0.70 | TBXAS1 (0.54) | TBXAS1FNTAFNTBPKMMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | claimed |
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | LUMINIDE | 2005-04-14 | — | — | US | disclosed |
| US-6555663-B1 | Pharmaceuticals which are activated intracellularly by reaction with cellular electron carriers or free radicals to cause release of a free and active drug molecule | MILLS RANDELL LEE (US) | 2003-04-29 | — | — | US | disclosed |
| EP-0414730-B1 | Chemical Compounds and pharmaceutical compositions capable of releasing a drug | MILLS RANDELL L (US) | 1999-12-15 | — | — | EP | disclosed |
| US-5773592-A | COMPRISES A CHEMILUMINESCENT MOIETY, A PHOTOCHROMIC MOIETY AND A BIOLOGICALLY ACTIVE AGENT CAPABLE OF BEING RELEASED | MILLS RANDELL LEE (US) | 1998-06-30 | — | — | US | disclosed |
| US-5428163-A | Luminides; chemiluminescence; redox system, releasing free drug | MILLS RANDELL L (US) | 1995-06-27 | — | — | US | disclosed |
| EP-0414730-A4 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | — | 1993-06-16 | — | — | EP | disclosed |
| EP-0414730-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | Mills, Randell L. (US) | 1991-03-06 | — | — | EP | disclosed |
| WO-1989009833-A1 | LUMINIDE AND MACROLUMINIDE CLASS OF PHARMACEUTICALS | MILLS RANDELL L (US) | 1989-10-19 | — | — | WO | disclosed |
| EP-0265129-A1 | Thrombolytic therapy | SMITHKLINE BEECHAM CORPORATION (US) | 1988-04-27 | — | — | EP | disclosed |
| US-4374845-A | INHIJBIT DIOSYNTHESIS OF THROMBOXANE A2, ANTIINFLAMMATORY, ANTICOAGULANTS, CARDIOVASCULAR DISORDERS | KISSEI PHARMACEUTICAL CO. (JP) | 1983-02-22 | — | — | US | disclosed |
| US-4346099-A | Carboxy-imidazole derivatives, compositions and use | ONO PHARMACEUTICAL CO., LTD. (JP) | 1982-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080260-A1 | Preparation of prodrugs for selective drug delivery | APEH, PAH, ALAD | TBXAS1 2312/4885FNTA 2619/4885FNTB 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.